Immunosuppression by mesenchymal stromal cells: From culture to clinic
Immunosuppression by mesenchymal stromal cells: From culture to clinic
复制标题
DOI：
10.1016/j.exphem.2008.03.006
复制
发表时间：
2008-06-01
影响因子：
2.6
通讯作者：
McTaggart, Steven J.
中科院分区：
文献类型：
--
作者：
Jones, Ben J.;McTaggart, Steven J.
广泛的体外研究表明，多能间充质基质细胞（MSC）可以通过调节细胞和先天免疫途径发挥深刻的免疫抑制作用。它们容易从许多组织中分离并离体扩增的能力使它们成为全身免疫抑制治疗的有吸引力的候选者。在这篇文章中，我们将审查最近的实验数据的机制，MSC抑制同种异体增殖反应和临床意义，其潜在的用途在造血干细胞移植，实体器官移植，和治疗自身免疫性疾病。虽然体外数据一致地证明了MSC的免疫抑制能力，但目前在动物和人类中的研究表明，MSC在产生全身免疫抑制方面效果较差。需要使用标准化细胞群进行进一步的机制研究和随机对照试验，以确定使用MSC作为免疫治疗的最佳条件。(C)2008 ISEH -血液学和干细胞学会。爱思唯尔公司出版
Extensive in vitro studies have shown that multipotent mesenchymal stromal cells (MSC) can exert profound immunosuppressive effects via modulation of both cellular and innate immune pathways. Their ability to be readily isolated from a number of tissues and expanded ex vivo makes them attractive candidates for systemic immunosuppressive therapy. In this article, we will review recent experimental data on the mechanisms by which MSC inhibit the alloproliferative response and the clinical relevance for their potential use in hematopoietic stem cell transplantation, solid organ transplantation, and treatment of autoimmune diseases. While in vitro data consistently demonstrate the immunosuppressive capability of MSC, current studies in animals and humans suggest that MSC are less effective in producing systemic immunosuppression. Further mechanistic studies and randomized controlled trials using standardized cell populations are needed to define the optimal conditions for the use of MSC as immunotherapy. (C) 2008 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.